Chemotherapy in bronchogenic carcinoma.
The effects of three different chemotherapeutic treatment regimens on the survival of one hundred inoperable lung cancer patients was studied in a randomized clinical trial. Of the patients 36 received cyclophosphamide as a single agent, 31 patients actinomycin D--vincristine combination and 33 patients cyclophosphamide--methotrexate--vincristine combination. Epidermoid carcinoma was the most sensitive to the actinomycin D--vincristine combination, whereas small cell anaplastic carcinoma responded to cyclophosphamide alone, and to the cyclophosphamide--methotrexate--vincristine combination. In spite of shrinkage of the tumour no differences were, however, observed in the survival times of the eifferent groups.
D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003609:Dactinomycin / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008727:Methotrexate / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D003609:Dactinomycin; D014750:Vincristine; D008727:Methotrexate